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Immunotherapy has become one of the most promising avenues for cancer treatment, 
making use of the patient’s own immune system to eliminate cancer cells. Clinical trials 
with T-cell-based immunotherapies have shown dramatic tumor regressions, being effec-
tive in multiple cancer types and for many different patients. Unfortunately, this progress 
was tempered by reports of serious (even fatal) side effects. Such therapies rely on the 
use of cytotoxic T-cell lymphocytes, an essential part of the adaptive immune system. 
Cytotoxic T-cells are regularly involved in surveillance and are capable of both eliminating 
diseased cells and generating protective immunological memory. The specificity of a 
given T-cell is determined through the structural interaction between the T-cell receptor 
(TCR) and a peptide-loaded major histocompatibility complex (MHC); i.e., an intracellular 
peptide–ligand displayed at the cell surface by an MHC molecule. However, a given TCR 
can recognize different peptide–MHC (pMHC) complexes, which can sometimes trigger 
an unwanted response that is referred to as T-cell cross-reactivity. This has become 
a major safety issue in TCR-based immunotherapies, following reports of melanoma- 
specific T-cells causing cytotoxic damage to healthy tissues (e.g., heart and nervous system). 
T-cell cross-reactivity has been extensively studied in the context of viral immunology and 
tissue transplantation. Growing evidence suggests that it is largely driven by structural 
similarities of seemingly unrelated pMHC complexes. Here, we review recent reports 
about the existence of pMHC “hot-spots” for cross-reactivity and propose the existence 
of a TCR interaction profile (i.e., a refinement of a more general TCR footprint in which 
some amino acid residues are more important than others in triggering T-cell cross- 
reactivity). We also make use of available structural data and pMHC models to interpret 
previously reported cross-reactivity patterns among virus-derived peptides. Our study 
provides further evidence that structural analyses of pMHC complexes can be used to 
assess the intrinsic likelihood of cross-reactivity among peptide-targets. Furthermore, 
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we hypothesize that some apparent inconsistencies in reported cross-reactivities, such 
as a preferential directionality, might also be driven by particular structural features of the 
targeted pMHC complex. Finally, we explain why TCR-based immunotherapy provides 
a special context in which meaningful T-cell cross-reactivity predictions can be made.
Keywords: t-cell cross-reactivity, peptide–MHC complex, cross-reactivity hot-spots, tCr-interacting surface, 
hierarchical clustering, tCr/pMHC, cancer immunotherapy
1. HypotHesis and tHeory
1.1. Cellular immunity, private specificity, 
and t-Cell Cross-reactivity
Cellular immunity relies on T-cell lymphocytes and their abil-
ity to produce unique T-cell receptors (TCRs), while humoral 
immunity relies on B-cell lymphocytes and their ability to 
produce antibodies (also referred to as B-cell receptors) (1, 2). 
Combined, these two branches compose the adaptive immunity, 
a major “upgrade” in the evolution of the immune system, first 
seen in jawed vertebrates (1, 2). Different from more ancestral 
mechanisms of innate immunity, adaptive immunity allows cre-
ating specific immune responses to virtually any new pathogen 
encountered by the host organism. It also allows generating 
immunological memory, protecting the host against future 
encounters with the same pathogen (3). This new system was 
essential in facing the threat of viruses, which are incredibly 
diverse and evolve at an amazing rate (4). While antibodies can 
neutralize circulating viruses, cytotoxic T-cells can find and 
eliminate infected cells (i.e., the “hijacked factories” producing 
new viral particles). In fact, coevolution with viruses is a major 
factor shaping the complexity and diversity of the mechanisms 
involved in cellular immunity (5–7).
The key players in this system are the major histocompatibility 
complex (MHC) molecules, a diverse set of protein receptors 
capable of binding peptides derived from intracellular proteins 
and displaying them at the cell surface (5). This allows circulating 
cytotoxic T-cells to interact directly with these peptide–MHC 
(pMHC) complexes, using their TCRs. After a complex selection 
process in early stages of their development (8, 9), T-cells are able 
to recognize “non-self ” pMHC complexes. For instance, a virus-
infected cell displays at its surface MHC molecules loaded with 
virus-derived peptides. These non-self pMHC complexes can 
trigger a T-cell response that, in turn, eliminates the infected cell. 
Moreover, the recognition of these non-self pMHCs can generate 
immunological memory against this particular virus strain (3).
The efficiency of antiviral immunity, however, depends on the 
ability of an individual to produce and store a pool of memory 
T-cells (i.e., a T-cell repertoire) able to specifically recognize most 
of the hugely variable pMHC complexes displayed by cells in dif-
ferent tissues. It actually is quite a puzzling task, if one considers 
(i) the diversity of MHC allotypes of the host (i.e., the number 
of MHC protein variants in the human population), (ii) the 
genetic variability of viruses (i.e., peptide diversity), and (iii) the 
frequency of viral infections. The solution to this puzzle involves 
a combination of two important features of cellular immunity: 
(i) somatic recombination of TCR-encoding genes and (ii) T-cell 
cross-reactivity. Somatic recombination allows for a potential 
combinatorial diversity of TCRs which exceeds 1020 (10, 11). 
Cross-reactivity allows optimizing the repertoire of T-cells for 
the recognition of most possible targets, despite the limited 
number of T-cells that can exist in a given individual, at a given 
time (≈1011 in humans) (10, 12). Each newly generated T-cell has 
a unique TCR and is added to the diverse repertoire of circulating 
T-cells. If activated by a given pMHC, one T-cell generates an 
entire pool of clone cells (referred to as a T-cell line). All these 
clones display essentially the same TCR and, therefore, are spe-
cific to the same (cognate) pMHC. However, after being added 
to the memory pool, some of these T-cells can be recruited in an 
initial response to a different heterologous pMHC (e.g., the same 
MHC displaying the peptide of a different virus).
T-cell cross-reactivity is defined as the ability of a given T-cell 
to be activated by two or more heterologous pMHCs (12). This 
cross-reactivity can even mediate heterologous immunity, when 
a contact with one pathogen generates a partial immunity 
against a second (heterologous) pathogen (13). Heterologous 
immunity is a double-edged sword: it can be protective and 
desired for wide spectrum vaccine development (14, 15), but it 
can also mediate impaired cellular response, chronic infection 
and immunopathology (15–18). The stochastic nature of TCR 
specificity generation entails that each individual has a unique set 
of TCRs (referred to as private specificity) (13). In addition, given 
the size limit of the T-cell repertoire and the constant challenges 
with a variety of pathogens, the memory pool of an individual 
is ever changing (e.g., some T-cell lines expand, others are lost) 
(19, 20). In time, cross-reactive cells represent an important part 
of our memory repertoire, and our immunity against every new 
challenge is directly influenced by our immunological history 
(12, 19, 21–23). Note that there exist some known biases in the 
somatic recombination process, producing some TCR sequence 
combinations with higher frequency in a population (24). This 
phenomenon is referred to as public TCR usage and will be 
discussed later (see section 1.4).
Recent studies are corroborating the idea that T-cell cross-
reactivity is the rule, rather than the exception (19, 22, 25, 26), 
and that structural features involved in specific TCR/pMHC 
interactions are the main features driving cross-reactive responses 
against heterologous targets (25, 27–29). Despite all the evidence 
accumulated in the context of viral immunity and tissue trans-
plantation, integration of T-cell cross-reactivity into other fields 
of immunology and human health has been rather slow. This 
delay can be partially explained by the complexity of the mecha-
nisms involved, as well as concerns about the reproducibility of 
experimental results characterizing T-cell cross-reactivity (26).
In a pioneering study, Wedemeyer and colleagues were able 
to collect T-cells recognizing a peptide derived from hepatitis 
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C virus (HCV), from the blood of healthy donors (30) who had 
no history of infection by HCV. This implied that these HCV-
specific T-cells were probably cross-reactive memory cells 
previously triggered by a heterologous pathogen. In fact, the 
authors were able to identify a peptide from influenza A virus 
(IAV) having 77% of sequence similarity with the HCV-derived 
peptide used to expand the T-cells. They also showed that these 
cells were able to recognize both peptides, and that T-cells with 
the same specificity were generated in response to IAV infection. 
However, a later study by Kasprowicz et al. (31) suggested that 
cross-reactivity between these heterologous peptides was rather 
weak and had a preferential directionality from HCV to IAV 
(i.e., T-cells primed with the HCV-derived peptide also recognize 
the IAV-derived peptide, but the opposite was usually not true) 
(31). More recent studies help clarify situations like this, showing 
that heterologous immunity between viruses is greatly influenced 
by private specificities and immunological history (19, 23, 32). 
Therefore, observed results are not solely determined by peptide 
sequence similarity, but also dependent on the particular T-cells 
dominating the response (in vivo), or the T-cell line selected for 
the experiments (in vitro or ex vivo) (24).
The rebirth of T-cell cross-reactivity as a major interest for 
human health, however, is coming from cancer research. For 
decades, immunologists have suggested that the same mecha-
nisms involved in antiviral surveillance were also involved in 
detecting and eliminating cancer cells, which can display MHCs 
loaded with tumor-specific peptides (33). More recently, the 
field of cancer immunotherapy has grown as one of the most 
promising paths for cancer treatment, relying on the mechanisms 
of cellular immunity to provide personalized therapies that can 
eliminate tumors in different tissues and even generate protective 
memory (33–36). A number of TCR-based therapies were put 
forward, making use of the latest molecular biology technologies 
to enhance TCR affinity against tumor-specific peptides (37). 
Unfortunately, the excitement was tempered by safety concerns. 
These supposedly tumor-specific T-cells can present unexpected 
T-cell cross-reactivities in some individuals, attacking healthy tis-
sues (38). In fact, off-target toxicity effects have been observed in 
recent clinical trials, with at least 5 deadly cases reported (39–41). 
Two of these cases were clearly linked to T-cell cross-reactivity 
between the targeted tumor-specific peptide (the melanoma-
associated antigen MAGE-A3) and a Titin-derived peptide 
expressed in healthy cardiac cells (39, 42). The peptides involved 
have only 55% of sequence similarity, exemplifying the great chal-
lenge faced by current preclinical screenings. Later analysis using 
X-ray crystallography confirmed the structural similarity of the 
corresponding pMHC complexes as the molecular basis for the 
observed T-cell cross-reactivity (43).
In response to this critical need, new computational approaches 
are being developed and tested to improve our capacity to 
screen for potentially dangerous cross-reactivities. Some of these 
methods involve assessing peptide sequence similarity, while 
also accounting for protein tissue expression and MHC binding 
(44, 45). Others are based on pMHC structural similarity (46–48) 
or some combination of previously mentioned features (49, 50). 
Despite the incredible challenge at hand and the current limita-
tions of these computational methods, encouraging results are 
being reported. For instance, some of these methods can predict 
the previously mentioned cross-reactivity between the peptides 
derived from MAGE-A3 and Titin. A better understanding of 
the mechanisms underlying T-cell cross-reactivity, as well as the 
relationship between structural features of pMHC complexes and 
the activation of T-cell clones, is of upmost importance to further 
improve these computational methods. In turn, such progress 
will allow us to provide useful predictions that can be directly 
translated to the clinic.
In the following sections we attempt to connect the dots 
between the current understanding of pMHC structure and the 
goal of making safer TCR-based immunotherapies. First, we 
review structural aspects of the TCR/pMHC interaction and 
introduce the idea of structural clustering of pMHC complexes 
(section 1.2). Then we apply clustering methods to both available 
crystallographic data and modeled pMHC complexes, providing 
further evidence that pMHC structural information is essential 
to understand T-cell cross-reactivity (section 1.3). Next, we 
review how structural features of the pMHC complex can 
actually shape the TCR repertoire (section 1.4). Going one step 
further, we hypothesize how the same features might be shaping 
different patterns of cross-reactivity: they can be responsible 
for weak cross-reactivity among similar peptide-targets (sec-
tion 1.5), or, conversely, drive cross-reactive responses among 
completely unrelated peptide-targets (section 1.6). Finally, we 
consider the implications of our work for T-cell cross-reactivity 
prediction and discuss why cancer immunotherapy provides 
a special context in which meaningful progress can be made 
(section 1.7).
1.2. structural analyses Can Uncover  
Key Features for t-Cell activation
For simplicity, we usually talk about cross-reactivity of TCRs that 
recognize different peptides, but it is important to keep in mind 
that the TCR does not recognize the peptide itself; it recognizes 
the combined surface of the pMHC complex (51). Therefore, 
observed cross-reactivities between peptides are linked to their 
presentation in the “context” of a particular MHC. Even if two 
different MHCs are capable of binding the same peptide, which 
is not common, the resulting pMHC complexes will most likely 
be different (52). In fact, this is one of the causes for rejection in 
(allogeneic) tissue transplantation (26, 53). In this study, we focus 
on cross-reactivity between peptides presented by the same class 
I MHC. However, cross-reactivity involving different MHCs has 
also been reported (53, 54), and the discussion presented here can 
also be extended to that context.
Studies using X-ray crystallography have greatly contributed 
to the current understanding of the TCR/pMHC interaction, 
which was recently reviewed by Degauque et al. (26). The TCR 
structure contains flexible loops that can come in contact with 
the TCR-interacting surface of the pMHC (i.e., the “face” of the 
pMHC complex exposed to TCR interaction; see Figures S1A–C 
in Supplementary Material). These loops include the complemen-
tarity-determining regions (CDRs), which are the most variable 
regions of the TCR structure and the result of the previously men-
tioned somatic recombination. Despite the structural flexibility 
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of these loops and the possibility of local conformational changes 
(25, 55), there is a conserved binding mode for the TCR/pMHC 
complex. Most times, the CDRs corresponding to the α chain 
of the TCR will interact with the amino-terminal portion of the 
peptide, while the β chain CDRs will interact with the carboxi-
terminal of the peptide, at a particular angle (26, 51) (Figure 
S1D in Supplementary Material). Note that the general docking 
mode of a TCR to its cognate pMHC is referred to as the TCR 
footprint (51). Although the mechanisms are still open for debate, 
recent studies suggest that the orientation of the TCR footprint 
is guided by genetically imprinted biases (on the TCR) to rec-
ognize conserved MHC amino acid residues (i.e., germline bias) 
(26, 29). However, with the accumulation of crystal structures 
and evidence from new experimental approaches, one can also 
see that different TCRs establish different interaction networks, 
and that some interactions on the pMHC surface seem more 
important than others to trigger recognition by a particular T-cell 
(24, 29). These special contacts have been previously referred to 
as hot-spots for T-cell cross-reactivity (25, 29, 56).
In previous work, our group described an in silico approach to 
evaluate the structural similarity of pMHC complexes (46, 48). 
We used hierarchical clustering as a tool to group pMHC 
complexes according to the similarity of their TCR-interacting 
surfaces. We also used available crystal structures as a reference 
to implement a method to model pMHC complexes for which 
no structural data were available (52, 57). Combining these 
methods, we were able to reproduce experimentally observed 
cross-reactivity patterns for a dataset of 28 naturally occurring 
variants of an HCV-derived peptide used for vaccine develop-
ment (CINGVCWTV) (46). We also applied these methods to 
predict potential cross-reactivities between this HCV vaccine 
peptide and a dataset of non-related virus-derived peptides, in 
the context of a particular human MHC (HLA-A*02:01) (46). 
Our predictions were later confirmed by in  vitro and ex vivo 
experiments (47), highlighting the prospecting potential of our 
methods. One of the detected cross-reactive peptides, derived 
from Epstein–Barr virus (LLWTLVVLL), shared no sequence 
similarity with the vaccine peptide. Notwithstanding, both pep-
tides show remarkably similar TCR-interacting surfaces when 
bound to HLA-A*02:01 (46, 47).
1.3. structural similarity of pMHC 
Complexes Can reveal their Likelihood 
for t-Cell Cross-reactivity
In 2010, Cornberg et al. (22) described cross-reactivity networks 
involving virus-derived peptides, within both human and murine 
memory T-cell pools (CD8+/CD44hi). They used as a reference 
a peptide derived from vaccinia virus (VV), corresponding to a 
9-mer sequence starting at position 198 of the A11 protein (here-
after denoted by VV-A11198). Using this VV-derived peptide, 
which is displayed by the murine MHC H-2Kb, the authors were 
able to activate three different memory T-cell populations that 
also recognized peptides from lymphocytic choriomeningitis 
virus (LCMV-GP34, LCMV-GP118, and LCMV-NP205). Therefore, 
VV-A11198 could be seen as a cross-reactivity “hub,” connected 
to all these LCMV-derived peptides (Figure 1A). The concept of 
cross-reactivity networks is interesting in highlighting how broad 
these T-cell cross-reactivities can be (25), sometimes involving 
completely unrelated targets. In this sense, graphical representa-
tions of such networks have been used in previous works (13, 50, 
58, 59). However, it is extremely important to keep in mind 
that despite providing a nice way to visually summarize cross-
reactivity relationships, the topology of these networks might 
not correspond to the cross-reactivities observed for a particular 
T-cell line. In other words, the “real” topology of the network 
in terms of T-cell activation depends on which T-cell is used to 
test these peptide-targets. In this study, we use cross-reactivity 
networks to summarize the information from previous studies, as 
a reference to analyze structural data and discuss cross-reactivity 
patterns (Figure 1). In our representation, each node describes a 
given peptide, and only peptides displayed by the same MHC are 
included in a given network (i.e., MHC-restricted network). Note 
that this is a schematic representation of the known relationships 
among peptides that are relevant to our discussion, and not a 
complete picture of known cross-reactivities; it is not expected 
to reflect the patterns observed in any particular T-cell assay. 
Additional information on all peptides included in our analysis 
can be found in Table S1 in Supplementary Material.
In their original study, Cornberg et  al. (22) suggested that 
observed cross-reactivity patterns present a within-individual 
variation driven by private specificities and immunological 
history. For instance, the authors were able to collect VV-A11198-
specific T-cells from mice previously immunized with LCMV 
(i.e., LCMV-immune mice). Note that if the donor had no previ-
ous contact with VV-derived peptides, these VV-A11198-specific 
T-cells should be cross-reactive cells primarily expanded in vivo 
by recognizing some LCMV-derived target. These cells were 
further expanded in vitro with the cognate (VV-A11198) peptide 
and challenged with different peptides derived from LCMV, VV 
and pichinde virus (PV). Interestingly, these VV-A11198-specific 
T-cells presented cross-reactivity with LCMV-GP34, LCMV-GP118, 
LCMV-NP205, and PV-NP205 (22) (Figure 2A). However, cross-
reactivity against another VV-derived peptide (VV-E7130) was 
not observed. On the other hand, a very different pattern was 
observed when the authors performed a similar experiment, but 
expanding VV-A11198-specific T-cells from VV-immune mice 
instead of LCMV-immune mice (Figure 2B). In this case, cross-
reactivity with VV-E7130 and LCMV-GP34 was observed, but no 
cross-reactivity was observed with LCMV-GP118, LCMV-NP205, 
and PV-NP205. These contrasting results suggest the use of a dif-
ferent T-cell population with a different specificity (22). They also 
suggest a greater structural similarity between VV-A11198 and 
LCMV-GP34, since this cross-reactivity was observed for both 
LCMV-immune and VV-immune background. In fact, structural 
similarity between these targets was later confirmed by Shen 
et al. (28), which solved the crystal structures of VV-A11198 and 
LCMV-GP34-C8M bound to H-2Kb (PDB codes 3TIE and 3TID, 
respectively).
Out of the 25 pMHCs included in our H-2Kb-restricted net-
work (Figure 1A), at the time of our analysis, only 6 had their 
structure determined by experimental methods. Using our pre-
viously described structure-based approach (46), we performed 
a hierarchical clustering of these 6 crystallographic structures 
FigUre 1 | Cross-reactivity networks (CRNs) compiled from previous publications. Arrows indicate the directionality of reactions observed experimentally, with 
colors indicating stronger (black) or weaker (gray) responses. Segmented connectors indicate non-cross-reactive targets. Each ellipse represents one peptide in  
the context of (a) murine H-2Kb, (B) human HLA-A*02:01, or (C) murine H-2Db MHC allotypes. Each ellipse contains the peptide sequence, abbreviation, and PDB 
code (when available). Ellipses’ colors indicate the source of the cross-reactivity information. Most data were compiled from Cornberg et al. (22) (orange and red 
ellipses) and expanded with data from Shen et al. (28) (cyan) and Fytili et al. (60) (yellow). Gray ellipses indicate data from Wlodarczyk et al. (17), and dark green 
ellipses indicate targets included based on sequential/structural analyses (see Methods and Resources). The symbol # was used to indicate reactions suggested by 
sequential/structural analyses that were not yet tested in vitro/in vivo. Purple areas indicate complexes with greater structural similarity according to our hierarchical 
clustering analyses.
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(Figure S2 in Supplementary Material). Supported by multiscale 
bootstrap resampling with the R package pvclust (61), the clus-
tering agreed with experimental data. The cross-reactive targets 
VV-A11198 and LCMV-GP34 fall in the same cluster; the same is 
observed for the highly cross-reactive targets LCMV-NP205 and 
PV-NP205. These four targets are closer to one another than to 
the non-cross-reactive target OVA258. Finally, the most different 
structure in this analysis contained the non-cross-reactive escape 
variant LCMV-NP205-V3A (21, 62).
To expand our analysis, we used the pMHC modeling method 
implemented in DockTope (52, 57), obtaining the structures 
of other complexes previously tested by Cornberg et  al. (22) 
(Figure  1A). We also included in this analysis two unrelated 
peptides, VV-C4125 and LCMV-GAG70, as putative non-cross-
reactive controls (Table S1 in Supplementary Material). Our 
expanded hierarchical clustering reflects the greater structural 
similarity between VV-A11198 and LCMV-GP34, since both 
complexes fall in the same cluster, with the edge presenting 
the lowest height and the highest p-values (Figure 3). Peptides 
LCMV-GP118 and VV-E7130, which are cross-reactive with 
VV-A11198, fall in the next branch, followed by a cluster with 
the other cross-reactive targets (LCMV-NP205 and PV-NP205). All 
these cross-reactive targets were grouped into a bigger cluster 
(see edge 5 in Figure 3), apart from all the non-cross-reactive 
targets. As discussed by Cornberg et  al. (22), these cross-
reactivities could not be easily predicted with peptide sequence 
FigUre 3 | Extended H-2Kb-restricted clustering. Structure-based hierarchical clustering performed with pvclust (61). Each putative cluster is represented by a 
specific edge (gray numbers), in order of increasing heights (y axis). Cluster confidence is measured with two p-values, approximately unbiased (AU), and bootstrap 
probabilities (BP). Lines highlighted in purple indicate structures with greater structural similarity (as represented in Figure 1). Lines highlighted in blue and pink 
indicate putative cross-reactivity thresholds for different memory T-cells (see Figure 2). Each peptide target is colored according to Figure 1. Peptide abbreviation 
and sequence are provided, with red amino acids indicating changes in relation to VV-A11198. *Crystal structure 3TID was used to represent LCMV-GP34, despite 
presenting a C8M exchange, as indicated by its sequence (see Methods and Resources).
FigUre 2 | Schematic representation of experimentally observed cross-reactivity patterns. Two alternative dendrograms were drawn to represent alternative 
outcomes observed in experiments previously performed by Cornberg et al. (22). (a) VV-A11198-specific T-cells recovered from mice previously immunized with 
lymphocytic choriomeningitis virus (LCMV) recognize the cognate peptide (indicated by the gray box) as well as three other peptides derived from LCMV and one 
derived from pichinde virus (PV). We can represent these connections as a “cross-reactivity-cluster” in our dendrogram, as indicated in red. Another peptide derived 
from vaccinia virus (VV-E7130), however, is not recognized. (B) VV-A11198-specific T-cells recovered from mice previously immunized with vaccinia virus (VV) recognize 
the cognate peptide (gray box) as well as the other VV-derived peptide (VV-E7130) and one LCMV-derived peptide (LCMV-GP34). However, in this experiment, no 
cross-reactivity was observed against peptides LCMV-GP118, LCMV-NP205, and PV-NP205 (indicated by the green bar). Although targeting the same VV-derived 
peptide, the alternative cross-reactivity patterns described in panels (a,B) reflect the use of different T-cell lines in each experiment (indicated as a blue or pink 
T-cell). Note that cross-reactivity between VV-A11198 and LCMV-GP34 was observed in both experiments, suggesting higher structural similarity of these peptides 
when displayed by H-2Kb. All peptides involved in these experiments are restricted to the murine MHC H-2Kb. This is a schematic representation, and the heights  
of the edges in the dendrogram do not capture the actual “distances” among the peptide-targets. Additional information on the presented peptides can be found  
in Table S1 in Supplementary Material.
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similarity, since all these peptides share less than 50% of their 
amino acid residues. For instance, sequence similarity between 
VV-A11198 and LCMV-GP34 is only 37.5%, the same as between 
VV-A11198 and the non-cross-reactive target OVA258. In spite of 
that, our results show that this cluster of cross-reactivity involv-
ing peptides from three different viruses could be predicted 
by an in  silico analysis of the corresponding pMHC structures 
(see edge 5 in Figure 3).
Cross-reactivity was indeed observed among these 6 peptides 
in the context of H-2Kb (22, 28). These pMHC complexes also 
present structural similarities, being clustered together in our 
structure-based hierarchical clustering. However, there was no 
experimental evidence of one T-cell population able to recognize 
all six peptides (22). As already discussed, cross-reactivity pat-
terns depend on the specific T-cell population tested. Assuming 
our clustering correctly captures the relationships among these 
pMHCs, in terms of structural similarity, we can make some 
inferences about the T-cells used in the aforementioned experi-
ments. We can say that T-cells from LCMV-immune mice are 
more cross-reactive, and we can visually represent them with 
a higher threshold in our clustering analysis (defining the blue 
cluster in Figure  3). Such threshold would correctly predict 
most of the observed cross-reactivities, with the exception 
of VV-E7130 (which was not recognized). On the other hand, 
T-cells from VV-immune mice can be represented with a 
lower threshold (defining the pink cluster in Figure  3), since 
VV-A11198-specific T-cells recognize neither NP205 peptides. The 
exception in this case, would be LCMV-GP118. These exceptions 
cannot be predicted considering the information provided by 
the pMHC structures, since they are most likely driven by TCR 
variability and private specificities. In spite of that, our data 
suggest a correlation between pMHC structural similarity and 
the probability to find cross-reactivity among pMHC targets; 
that is, the higher the similarity, the higher the likelihood of 
observing cross-reactive responses. Although cross-reactivity 
between LCMV-GP118 and VV-E7130 was not observed using the 
VV-A11198-specific or VV-E7130-specific T-cells (22), the simi-
larity of these pMHC complexes (Figure S3 in Supplementary 
Material) suggests that this cross-reactivity should be observed 
using another T-cell population; maybe with LCMV-GP118-
specific T-cells.
1.4. structural Features of the pMHC  
Can shape the tCr repertoire
More than a decade ago, Turner and colleagues (63) described 
differences in the T-cell population stimulated by a featureless 
peptide (referred to as a “vanilla” peptide), and a peptide having 
a prominent feature exposed to the TCR (hereafter referred to as 
a “spicy” peptide). The authors used a peptide derived from the 
polymerase acidic protein of influenza A virus as an example of 
spicy peptide (IAV-PA224, see Table S1 in Supplementary Material). 
This peptide has an arginine at position 7 (P7), which becomes 
an exposed feature when displayed by the murine MHC molecule 
H-2Db (Figure S4 in Supplementary Material). Immunization 
with this peptide triggered the expansion of a very diverse pool 
of T-cells, including cells with high affinity to the target pMHC. 
Comparing the response across different animals, the authors 
noticed great variability in TCR usage. In other words, in each 
animal the response was dominated by TCRs with unique CDR 
sequences (i.e., shaped by private specificity).
Surprisingly, opposite results were observed when using a 
vanilla peptide. Immunization with a mutated version of IAV-PA224, 
replacing the arginine at P7 with an alanine (IAV-PA224-R7A), 
triggered the expansion of a much less diverse T-cell population. 
In this case, similar CDR sequences were observed for differ-
ent individuals (i.e., public TCR usage). The same results were 
observed with a wild-type vanilla peptide (IAV-NP366). Therefore, 
structural features of the pMHC complex can shape the composi-
tion of the TCR repertoire during a cellular immune response. 
A pMHC displaying a vanilla peptide has a TCR-interacting sur-
face dominated by the (self) MHC; given the negative selection of 
T-cells, very few available TCRs can recognize this complex. This 
could explain the observation of a less diverse population and 
the use of public TCRs, sharing a germline bias to interact with 
the MHC. In addition, we could expect such TCRs to be more 
cross-reactive, since they rely mostly on (self) MHC features for 
the recognition. On the other hand, a spicy peptide offers a more 
evident discerning feature that various TCRs can recognize (in 
slightly different ways). Given their “focus” on this outstanding 
feature, we could expect such TCRs to be intrinsically less cross-
reactive and they should be incapable (or impaired) to recognize 
pMHCs lacking such feature.
It is easier to understand this analogy of the spicy feature 
having in mind some prominent structure that is specific to 
the peptide, as the examples mentioned earlier and in the next 
section. However, the TCR/pMHC interaction can be influenced 
by more subtle features, as recently described by Song et  al. 
(24). They performed a comprehensive evaluation of the T-cell 
response to the peptide IAV-M158, displayed by HLA-A*02:01, 
using the next-generation sequencing of TCRs. In addition, 
they resolved the crystal structures of two selected TCR/pMHC 
complexes. IAV-M158 has been described as a vanilla peptide, 
since most of its side chains are buried when displayed by HLA-
A*02:01. In turn, it was suggested that the lack of recognizable 
peptide features would lead to a very narrow T-cell response 
(i.e., lack of TCR diversity among stimulated T-cells). However, 
Song et al. (24) observed that the IAV-M158:HLA-A*0201 complex 
can actually be recognized by a broad range of TCRs; most of 
them sharing the same Vβ domain. They were also able to iden-
tify a conserved structural feature that seemed to be required for 
the recognition of this peptide. Interestingly, it was not something 
“prominent,” and it was not exactly a feature of the peptide alone. 
In fact, the authors describe a unique exposed pocket between the 
peptide and the MHC, with which very different TCRs are able to 
interact. In other words, this particular pocket is a recognizable 
structural feature that is specific to the IAV-M158:HLA-A*0201 
complex. As a result, in the context of our discussion, we can 
describe IAV-M158:HLA-A*0201 as a spicy complex. The lack 
of a prominent peptide feature might facilitate the selection of 
some public TCRs, as indeed observed experimentally (24). 
But the pMHC-specific pocket allows the selection of a broad 
TCR repertoire, in the same way as for spicy peptides. Once 
again, these findings highlight the fact that in most cases we 
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cannot discuss T-cell activation or T-cell cross-reactivity only in 
terms of peptide-targets, since the key features for recognition 
might come from the unique combined structure of the pMHC 
complex.
1.5. Local structural differences among 
pMHC Complexes Can account for 
Limited Cross-reactivity and Lack  
of reciprocity
In a recent study, Wlodarczyk et al. (17) described a weak cross-
reactivity between IAV-PA224:H-2Db and a heterologous complex 
displaying a peptide derived from lymphocytic choriomeningitis 
virus (LCMV-GP276:H-2Db, see Table S1 in Supplementary 
Material). Since crystal structures are available for both com-
plexes, we can visually compare their TCR-interacting surfaces 
(Figures  4A–C). Notably, LCMV-GP276:H-2Db differs from 
IAV-PA224:H-2Db by not having the featured arginine at P7. 
As expected, using our structure-based hierarchical clustering, 
we can see greater proximity (i.e., structural similarity) between 
LCMV-GP276:H-2Db and IAV-PA224-R7A:H-2Db, than between 
these complexes and the wild-type (IAV-PA224:H-2Db) or the 
non-cross-reactive complex IAV-NP366:H-2Db (Figure S5 in 
Supplementary Material). As described by Wlodarczyk et al. (17), 
cross-reactivity between GP276:H-2Db and IAV-PA244:H-2Db was 
weak and showed a preferential directionality. From the pool of 
T-cells recognizing GP276:H-2Db (primer) it was possible to extract 
T-cells that also recognize IAV-PA224:H-2Db (i.e., heterologous 
challenge). However, the reverse experiment was not successful.
Taken together, these results allow us to postulate that immu-
nization with IAV-PA224 stimulates a pool of T-cells dominated 
by clones with high specificity to the spicy feature (in this case, a 
peptide feature: the R at P7). By challenging with a heterologous 
peptide that lacks this prominent feature, we would most likely 
fail to find a T-cell clone that can also recognize the heterologous 
vanilla peptide-target (e.g., LCMV-GP276). However, by using the 
vanilla peptide as a primer, we would start from a population of 
T-cells that is less diverse (i.e., dominated by public TCRs) but 
more cross-reactive. These TCRs are primarily engaging with 
(self) MHC structural features; some of these clones might also 
recognize the heterologous spicy peptide (IAV-PA224), regard-
less of the prominent amino acid residue at P7. We believe this 
recognition might involve some adjustment of the CDR loops 
around the center of the peptide, as recently discussed by Adams 
et al. (29). Naturally, some TCRs will not be able to undergo such 
adjustment and will not show cross-reactivity. We also hypoth-
esize that the “stronger” the spicy feature (or the combination of 
diverging features), the stronger the directionality and the lower 
the likelihood of cross-reactivity. Conversely, we believe stronger 
cross-reactivity should be observed between very similar pMHC 
complexes, regardless of directionality. For instance, stronger 
cross-reactivity should be observed between LCMV-GP276:H-2Db 
and the mutated IAV-PA224-R7A:H-2Db, than with the wild-type 
(Figure 1C).
Additional examples supporting this theory can also be 
found in the context of human MHCs. By the time of our 
analysis, out of the 9 virus-derived peptides included in our 
HLA-A*02:01-restricted network (Figure 1B), only 4 had avail-
able crystal structures. We modeled the remaining complexes and 
performed a hierarchical clustering (Figure S6 in Supplementary 
Material). As expected, the cross-reactive peptide-targets EBV- 
BMLF1300, IAV-M158, HCV-NS31073, HIV-GAG77, and EBV-
LMP2329 were clustered together (see edge 5 in Figure S6 in 
Supplementary Material). These last two structures were actually 
the most similar pair of structures inside this cluster, in agree-
ment with previous clustering results from our group (46).
Two non-cross-reactive variants of HCV-NS31073 derived 
from HCV genotype 3, previously referred to as G3-14 and 
G3-18 (46, 60), fell in separate branches. Despite being the 
outermost branch of the main cluster (see edge 6 in Figure S6 in 
Supplementary Material), the small distance between G3-14 and 
the cross-reactive targets suggest that cross-reactivity with this 
HCV-derived escape variant might be observed depending on 
the T-cell population tested. Interestingly, the complex present-
ing EBV-BRLF1109 falls in the same branch as G3-18, which is far 
from its cross-reactive target (EBV-BMLF1300). This HCA result 
was due to a negatively charged spot in the surface of the EBV-
BRLF1109:HLA-A*0201 complex, which was not seen in its cross-
reactive counterparts (Figures  4D–F). If we remove from our 
analysis this negatively charged spot, EBV-BRLF1109 is clustered 
with EBV-BMLF1300 (Figure 5). Note that we have had access to a 
yet unpublished crystal structure of EBV-BRLF1109:HLA-A*0201, 
recently resolved by the team of Dr. Lawrence Stern (UMass 
Medical School, MA, USA), which confirms the existence of 
the outstanding negatively charged spot observed in our model 
(Song I, personal communication, June 2017).
Similar to the situation described for IAV-PA224, cross-
reactivities involving EBV-BRLF1109 feature several peculiarities. 
For instance, they are not observed for most T-cell populations 
and normally respect a given directionality, from EBV-BMLF1300 
to EBV-BRLF1109 (22). EBV-BRLF1109-specific T-cells recovered 
from EBV-immune individuals and expanded in vitro in the pres-
ence of the cognate peptide present higher affinity/avidity in TCR/
pMHC interaction. Note that these cells are not cross-reactive 
with EBV-BMLF1300. On the other hand, EBV-BMLF1300-specific 
T-cells expanded in vitro in the presence of the cognate peptide 
might also recognize EBV-BRLF1109 (22). Further expansion 
of this population with the heterologous peptide (i.e., EBV-
BRLF1109) produces (cross-reactive) EBV-BRLF1109-specific 
T-cells with lower affinity/avidity in TCR/pMHC interaction 
(data not shown).
It is known that TCRs usually interact with pMHCs using a 
“canonical” binding mode (25, 51, 65, 66), but it was shown that 
a given TCR can preferentially use distinct amino acid residues 
to come in contact with different complexes (67) or even modify 
its CDR loops to accommodate different peptides (68). Therefore, 
it can be argued that immunization with a spicy peptide (such as 
IAV-PA224 or EBV-BRLF1109) will trigger a highly polyclonal T-cell 
response, with a broad spectrum of TCR specificities. Some of 
these are less specific to the homologous target, and more cross-
reactive with other peptides, probably by establishing an interaction 
“focused” on surface regions that are shared among these targets 
(Figure 4). On the other hand, some of these cells present higher 
affinity/avidity with this homologous peptide, by establishing an 
FigUre 4 | Structural similarity between cross-reactive complexes. TCR-interacting surfaces of selected pMHC complexes were computed with Grasp2 (64). The 
rows correspond to different datasets of cross-reactive complexes. The central column indicates the reference (cognate) complex in each row (B,e,H). The left 
column indicates a known complex with limited cross-reactivity (a,d,g), while the right column indicates a highly cross-reactive complex (C,F,i). MHC heavy chain 
domains α1 and α2 are indicated in each complex, as well as the region corresponding to the peptide (black rectangle). Colors indicate the range of the electrostatic 
potential over the surface, from −5 kT/e (red) to +5 kT/e (blue). Complex information and peptide sequence are depicted below each pMHC. For crystal structures, 
the corresponding PDB ID is also provided. Complexes with no published crystal structure were modeled (see Methods and Resources). Peptide sequences in each 
line indicate mutations in relation to the corresponding reference peptide (central column). Green arrows highlight “spicy” features of peptides with “limited” 
cross-reactivity (left column). Black and gray arrows indicate the intensity and preferred directionality of cross-reactivities observed in vitro. The symbol # indicates a 
cross-reactivity that is suggested by our structural analyses, but that was not yet tested experimentally.
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interaction “focused” on unique features of its surface (Figure 5). 
In turn, cross-reactivity between a spicy and a vanilla peptide 
depends on which T-cell populations are being tested.
We here hypothesize that, despite different TCRs can share 
a similar TCR footprint or even interact with the same pMHC 
amino acid residues, each TCR has a specific “interaction profile.” 
FigUre 5 | Structural features of different regions produce alternative clusters. Schematic representation of the structural relationships among three HLA-A*02:01-
restricted complexes displaying the virus-derived peptides EBV-BMLF1300, EBV-BRLF1109, and HCV-NS31073_varG3-18. Peptide sequences indicate the differences 
in relation to EBV-BRLF1109. (a) Focusing the analysis on the region in contact primarily with the TCR’s Vα domain (as in Figure S1E in Supplementary Material), we 
observe greater structural similarity between EBV-BRLF1109 and HCV-NS31073_varG3-18, while EBV-BMLF1300 stands out as an unrelated complex. Cross-reactivity 
between EBV-BRLF1109 and HCV-NS31073_varG3-18 is suggested by our structural analyses but has not yet been tested experimentally. (B) Focusing the analysis on 
the region in contact primarily with the TCR’s Vβ domain (as in Figure S1F in Supplementary Material), the three complexes become much more similar, with slightly 
bigger topographical differences for HCV-NS31073_varG3-18. Cross-reactivity from EBV-BMLF1300 to EBV-BRLF1109 has been observed experimentally, in this 
preferred direction. Although both TCR domains are interacting with the pMHC surface at the same time, there is experimental evidence that one of the domains 
can be more critical than the other to recognize a given complex (24). The highlighted areas on the pMHC surfaces were arbitrarily defined, for illustration purposes, 
and do not correspond to the footprint of any particular TCR. In the same way, the heights of the edges in the dendrogram do not capture the actual “distances” 
among the complexes. The corresponding PDB code is provided for crystal structures; remaining complexes were modeled (see Methods and Resources). The 
colors over the surfaces indicate the range of charge distribution, from −5 kT/e (red) to +5 kT/e (blue). Additional information on the displayed peptides can be 
found in Table S1 in Supplementary Material.
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That is, some TCR/pMHC interactions are more important than 
others for triggering the T-cell response, and this interaction 
profile is specific to each TCR (Figures S1E,F in Supplementary 
Material). Knowing the specific hot-spots of a cognate pMHC, 
i.e., the aforementioned “focus” of the TCR, would be key to 
predict cross-reactivity against heterologous pMHC targets. 
Moreover, although we tend to think of these hot-spots as 
pMHC amino acid residues, we need to expand this concept to 
11
Antunes et al. Structural Basis for T-Cell Cross-reactivity
Frontiers in Immunology | www.frontiersin.org October 2017 | Volume 8 | Article 1210
account for more subtle features of the TCR/pMHC interaction 
(e.g., pockets, hydrogen bonds, van der Waals contacts, and 
coordination of water molecules) (24).
1.6. t-Cell Cross-reactivity Can Be 
triggered by High-affinity interactions 
with specific structural Features of the 
pMHC Complex
We previously suggested that T-cells expanded in response to 
a vanilla peptide should be intrinsically more cross-reactive, 
since they are focused on patterns shared across different pMHC 
complexes. Conversely, T-cells expanded in response to a spicy 
peptide are expected to be less cross-reactive in general, since 
most heterologous peptides would lack the spicy feature that is 
the focus of the response. However, these cells should still be 
cross-reactive with peptides having the spicy feature, in some 
cases regardless of other evident differences.
In fact, studies in cancer immunotherapy show that mutations 
leading to increased affinity of a given TCR-peptide interaction 
can actually increase cross-reactivity (38–40, 69). We hypothesize 
that although not changing the overall TCR footprint, such 
mutations can change the interaction profile of the TCR. In other 
words, the enhanced peptide-specific interaction becomes much 
more important for T-cell activation than the additional pMHC 
interactions, and any heterologous pMHC sharing the structural 
feature recognized by this enhanced TCR can become a cross-
reactive target.
Further evidence for this hypothesis comes from a recent 
publication by Adams et  al. (29). Using a carefully designed 
experimental approach, the authors investigated cross-reactive 
peptides showing limited sequence identity with the reference 
cognate peptide (restricted to H-2Kd). Despite apparent sequence 
diversity among peptides recognized by the probe TCR, closer 
analysis revealed a repeated focus on structurally and chemi-
cally similar elements of the peptides. For instance, the authors 
describe a preferred interaction with hydrophobic amino acid 
residues at P7; particularly phenylalanine. The authors refer to 
this amino acid residue as a peptide hot-spot for cross-reactivity, 
which in combination with some germline-mediated interac-
tions greatly constrains the actual pool of potential cross-reactive 
pMHC targets (for the probe TCR). They also relate this descrip-
tion of the TCR/pMHC interaction with a more general feature 
of protein-protein interactions: a few energetically important 
contacts (usually in the center), surrounded by weaker and more 
diverse peripheral interactions. In the context of our discussion, 
we could see the phenylalanine at P7 as a spicy feature of the 
cognate peptide and the most important contact in the interac-
tion profile of the probe TCR.
As mentioned earlier, we have previously described cross-
reactivity between peptides with no sequence similarity, but with 
remarkably similar TCR-interacting surfaces (Figures  4G–I). 
The results described by Song et al. (24) provide an interesting 
example in which even greater variability can be anticipated. 
If the main feature for TCR recognition is a pocket defined by the 
peptide in the MHC cleft (e.g., IAV-M158:HLA-A*0201), we can 
expect that such “pocket-specific” T-cells will be cross-reactive 
to other pMHC complexes having a similar pocket, maybe 
regardless of other differences in the TCR-interacting surface. 
For instance, it is possible for a completely unrelated pMHC (with 
a different peptide sequence and/or MHC allotype) to have a very 
similar pocket and, therefore, be a cross-reactive target for IAV-
M158-specific T-cells.
As also discussed by Adams et al. (29), the implications of such 
“hot-spots” for cross-reactivity prediction are clear. A superficial 
look at the sequence diversity of cross-reactive peptides might 
suggest a completely promiscuous recognition, even considering 
a single TCR. The picture becomes even more complex if on top 
of that we start considering different pools of T-cells or the in vivo 
response of different individuals, which adds variability given 
to private specificity and immunological history. This complex 
picture helps understand the challenge of comparing results from 
different studies and drawing general conclusions about T-cell 
cross-reactivity. On the other hand, the characterization of cross-
reactivity hot-spots and TCR-specific interaction profiles should 
allow us to focus our research and make progress for meaningful 
cross-reactivity predictions.
In fact, Arber et al. (56) published a study that goes in this very 
direction. They combined T-cell assays and computational anal-
ysis to evaluate T-cell cross-reactivity of different clones in the 
context of cancer immunotherapy. Based on IFN-γ production 
against a panel of alanine-exchanged variants of the cognate pep-
tide, they defined T-cell-specific sequence motifs. These motifs 
were meant to capture T-cell-specific cross-reactivity hot-spots; 
they were later used for a sequence-based screening of potential 
cross-reactive targets in the human proteome. A number of posi-
tive hits were selected and tested experimentally, confirming that 
one T-cell line was much safer (i.e., less cross-reactive) than the 
other. The scope of this screening was still limited, not account-
ing for structural information of the pMHC or other potentially 
relevant features (14, 24, 70). Nevertheless, it provides us with 
an example of the type of framework that would be required for 
T-cell-specific prediction of potential cross-reactive targets.
1.7. Conclusions and implications for 
Cancer immunotherapy
Several immunotherapy trials are currently underway in a num-
ber of different tumor types to target tumor-associated peptides 
(71), including the melanoma-associated antigens MAGE-A3 
and MART-1. These tumor antigens are expressed by multiple 
tumor types (39) but are not expressed by most normal tissues. 
Since MART-1 is highly expressed in both melanoma and normal 
melanocytes, MART-1 TCR-based therapies have led to antitumor 
responses concurrent with vitiligo and melanocyte destruction in 
the eye and inner ear, side effects that could be relieved with ster-
oid administration (72). However, more severe safety issues with 
other TCR-based therapies have raised major concerns about this 
approach (33, 73, 74). As mentioned earlier, fatal adverse events 
were reported following adoptive transfer of TCR-transduced 
T-cells targeting complexes displaying the MAGE-A3 peptide 
(39–42). In two of these patients, unexpectedly severe cardiac 
toxicity was attributed to recognition of a completely unrelated 
peptide. This heterologous peptide-target was derived from the 
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self protein Titin and displayed by HLA-A*01:01 at the surface 
of healthy cardiac cells (43). As discussed by Stone et  al. (38), 
T-cell cross-reactivity becomes specially relevant in the context 
of affinity-enhanced TCRs. Approaches like this are becoming 
more popular through the use of chimeric antigen receptors 
(CARs) (71). However, as reported by van den Berg et al. (41), 
severe off-target reactions can occur even without TCR-affinity 
enhancement. And this adds a layer of concern on top of toxicity 
and autoimmunity that might occur even with the use of autolo-
gous tumor infiltrating T-cells (72, 75). Moreover, as highlighted 
in our review, T-cell cross-reactivity seems to be rather the rule 
than the exception. Therefore, despite all mechanisms of central 
and peripheral tolerance (76), off-target toxicity mediated by 
T-cell cross-reactivity must be a concern in any TCR-based 
immunotherapy. However, the risk for off-target toxicity will 
differ depending on which specific form of therapy is being used.
Our study corroborates the idea that structural similarity 
among pMHC complexes is one of the main features driving the 
likelihood of cross-reactive T-cell responses. Cross-reactivity is 
very likely to be observed between two structurally identical com-
plexes, for most T-cell lines recognizing one of the complexes, and 
in both directions. On the other hand, finding a T-cell line capa-
ble of recognizing two completely different pMHC complexes is 
highly unlikely. However, in most cases, two complexes will have 
common features but also different ones. In this situation, cross-
reactivity can only be assessed by the level of pMHC structural 
similarity, as an intrinsic likelihood. However, its occurrence, 
intensity and directionality will be driven by the specific T-cell 
population stimulated by the first target and selectively expanded 
after heterologous challenges.
In the context of polyclonal T-cell populations, this outcome 
is mostly a consequence of private specificity and immunological 
history (19, 20, 32). Therefore, predicting patient cross-reactivity 
in response to immunization, infection or tissue transplanta-
tion is very challenging. Even knowing the peptide-targets and 
the MHC alleles of the patient, and having the perfect tools to 
estimate intrinsic cross-reactivity probabilities, we would still 
lack information on the available T-cell repertoire and the inter-
action profile of the dominating T-cell line. On the other hand, 
some problems in cancer immunotherapy offer a much more 
constrained scenario. In the context of TCR-based immunothera-
pies, researchers know which TCR is being used to recognize 
the tumor-derived peptide-target and can ensure that this will 
be the dominating population during treatment. By narrowing 
our analysis to a particular therapeutic T-cell line, we can limit 
the scope of cross-reactivity to structural features of the targeted 
pMHC; more specifically, to hot-spots that are the focus of the 
therapeutic TCR.
Therefore, we advocate that an important goal of structural 
analyses in the field of immunotherapy should be the characteri-
zation of the TCR-specific recognition profile. This profile should 
be a refinement of a more general TCR footprint, highlighting 
which pMHC structural features are more important for trigger-
ing this particular T-cell. In turn, this information can be used 
to guide large-scale in silico screenings, based on a combination 
of structural and sequential information. Currently, no tool can 
perform such screenings in a personalized fashion, especially 
when considering the diversity of MHC alleles in the human 
population (5). However, T-cell cross-reactivity prediction will 
soon be enabled by advances in both pMHC structural modeling 
and TCR sequence analyses.
On the pMHC side, the combination of new modeling meth-
ods (57, 77) and structural clustering approaches (48, 78, 79) 
will allow considering structural information for larger datasets, 
regardless of whether experimental data are available. On the 
TCR side, recent reports have shown exciting results in the iden-
tification of conserved CDR motifs that can be directly linked 
to TCR specificity (11, 80). In time, we should be able to define 
T-cell-specific interaction profiles based on the sequence of the 
CDR regions of the TCR of interest.
Finally, better understanding of all subtle structural features 
relevant to TCR/pMHC engagement (11, 24) and their contri-
butions to TCR binding affinity (37, 81–83) will also facilitate 
efforts toward TCR engineering and rational design (37, 84–86). 
The TCR-specific interaction profile can inform computer-aided 
efforts to increase TCR affinity to tumor-specific peptides, while 
reducing the risk for off-target toxicity. Hopefully, the combined 
use of these new technologies will soon allow researchers to 
predict and validate potentially dangerous cross-reactivities in 
the early stages of therapy development, guiding additional pro-
cedures to achieve safer TCR-based immunotherapies. Despite 
the overall complexity of the subject, urgent needs in cancer 
immunotherapy are pushing the discussion forward and should 
pave the way for many additional contributions to other areas of 
human health.
2. MetHods and resoUrCes
2.1. experimental data on Cross-reactivity 
networks
Cross-reactivity networks depicted in Figure 1 were compiled from 
previously published experiments. Most data were made available 
by Cornberg et al. (22), who first presented these networks. The 
authors also described an escape variant of LCMV-NP205 with 
a V3A substitution (21), suggested its sequence similarity with 
peptides from old world arenaviruses (MOPV-NP205 and LASV-
LNP209) and finally solved its 3D crystal structure in the context 
of H-2Kb (62). This study with murine cross-reactivities was 
further explored by Shen et al. (28). The murine H-2Db-restricted 
network was depicted with data from Wlodarczyk et al. (17).
Cornberg et al. (22) also described a human HLA-A*02:01-
restricted network. We expanded this network by including 
a cross-reactive target prospected through structural in  silico 
analysis (46) and already confirmed experimentally (47), as well 
as two non-cross-reactive targets described by Fytili et al. (60). 
These tested non-cross-reactive targets were included both in 
human and murine cross-reactivity networks to provide further 
experimental information to guide our structure-based analysis.
A careful verification of peptides’ information was performed 
to determine the correct protein name and peptide position, 
providing an updated reference for future studies (Table S1 in 
Supplementary Material). Curated information from Uniprot 
(87) was used as the main reference, and GenBank (88) was also 
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consulted. References to the Immune Epitope Database (IEDB) 
(89), the Protein Data Bank (PDB) (90), and the CrossTope 
Database (91) were also provided, when available.
2.2. Crystal structures
Crystal structures were obtained from the Protein Data Bank 
(PDB) (90) and revised as needed using the PyMOL Viewer (92). 
The resulting pMHC structure was submitted to a short energy 
minimization with the Gromacs 4.5.1 package (93).
Note that 3TID is referred to as the crystal structure of 
LCMV-GP34:H-2Kb complex, despite presenting an amino acid 
exchange at P8 (LCMV-GP34-C8M). According to the authors 
who described the structure (28), this exchange has no signifi-
cant impact on TCR/pMHC interactions and this C8M variant 
was used in previous studies as an “equivalent” to the wild-type 
sequence. Here, sequence divergence between LCMV-GP34 and 
LCMV-GP34-C8M is indicated in Figure 3, but 3TID was consid-
ered as the crystal structure of LCMV-GP34 for all structure-based 
analyses.
2.3. Modeled structures
Peptide–MHC complexes without published crystal structures 
were predicted using the DockTope webserver (57). Briefly, a ref-
erence crystal structure of the MHC allotype of interest (without 
its ligand) was used as a receptor (“MHC_donor”) for a molecular 
docking with Autodock Vina 1.1.2 (94). The input ligand struc-
ture was produced by mutating a peptide structure obtained 
in the context of the same MHC allotype (“Peptide_pattern”). 
The resulting pMHC structure was then refined through a full 
atom energy minimization step with the Gromacs 4.5.1 package 
(93). A new docking search was performed with only the peptide 
side chains being flexible. This automated approach for pMHC 
structure prediction was largely validated against available crystal 
structures (57).
2.4. electrostatic potential Calculation  
and image analysis
Electrostatic potential over the TCR-interacting surface of 
pMHCs (for both crystals and models) was calculated using 
Delphi (95), through the molecular viewer software GRASP2 
(64). Automated scripts were used to prepare the structures for 
this analysis, allowing all pMHCs to be observed in the same fixed 
orientation. Images of the TCR-interacting surfaces were saved 
and imported to the ImageJ 1.46r software (National Institute 
of Health, USA, https://imagej.nih.gov/ij/). Using preexisting 
classes from ImageJ, our team adapted a plugin to import RGB 
values from predetermined regions over the pMHC surface (as in 
Figure S1D in Supplementary Material), following a previously 
described protocol (46, 47). Values were exported as “csv” tables 
and used as input for hierarchical cluster analysis.
2.5. Hierarchical Cluster analysis
In this study, hierarchical clustering was used as a tool to assess 
structure-based similarity among pMHC complexes. Input 
values were extracted from the images of the TCR-interacting 
surfaces (see section 2.4). Hierarchical clustering was performed 
with pvclust (61), an R package for assessing the uncertainty in 
hierarchical clustering. The “average” linkage method was used 
with “correlation” distance, and the number of bootstrap repli-
cations was set to 10,000. Results were plotted as dendrograms 
with approximately unbiased (AU) and bootstrap probabilities 
(BP) p-values. BP values are calculated by normal bootstrap 
resampling, and AU values are computed through multiscale 
bootstrap resampling, which is considered a better approxima-
tion to unbiased p-value (61). SEs for AU p-values were obtained 
with seplot, presenting values lower than 0.01 for all clusterings 
performed.
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taBLe s1 | List of all studied complexes. Identification and source information 
for each peptide and MHC, as well as corresponding access codes to relevant 
databases.
FigUre s1 | The TCR-interacting surface and the proposed TCR interaction 
profiles. (a) Top view of a pMHC complex depicting the MHC-receptor as 
cartoon (gray) and the peptide–ligand as sticks (pink). (B) Top view of the same 
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pMHC complex, depicting the exposed surface of the MHC (gray) and the 
exposed surface of the peptide (pink). (C) The combined surface of the pMHC 
complex, with the colors indicating the range of charge distribution over the 
surface from −5 kT/e (red) to +5 kT/e (blue). This is the “face” of the pMHC 
exposed for TCR recognition, referred to as the TCR-interacting surface. (d) The 
TCR binds to the pMHC in a conserved orientation: the TCR’s variant domain  
Vα primarily interacts with the N-terminal portion of the peptide, while the  
Vβ domain primarily interacts with the C-terminal portion of the peptide. This  
area of TCR/pMHC interaction, in a particular docking angle, is referred to as the 
TCR footprint. (e) Schematic representation of a TCR-specific interaction profile 
over the pMHC surface. Colored boxes indicate “hot-spots” for cross-reactivity 
(green) and secondary contacts that also contribute to TCR binding affinity 
(yellow). (F) Schematic representation of a different interaction profile, displayed 
by a different TCR that still shares the same general TCR footprint. Both depicted 
profiles are simplified schematic representations and do not represent known 
interactions of a any particular TCR.
FigUre s2 | Crystal-based H-2Kb-restricted clustering. Structure-based 
hierarchical clustering performed with pvclust (61). Each putative cluster is 
represented by a specific edge (gray numbers), in order of increasing heights  
(y axis). Cluster confidence is measured with two p-values, approximately 
unbiased (AU) and bootstrap probabilities (BP). Lines highlighted in purple 
indicate structures with greater structural similarity (as represented in Figure 1). 
Peptide abbreviation and corresponding PDB code for each crystal structure  
(in blue) are provided. *Crystal structure 3TID was used to represent LCMV-GP34, 
despite presenting a C8M exchange (see Methods and Resources).
FigUre s3 | TCR-interacting surfaces of predicted cross-reactive targets. 
Regions with positive (blue) and negative (red) charges are represented with a 
scale from −5 to +5 kT/e. Information on the corresponding peptide and MHC 
restriction is provided below each complex. Amino acid exchanges in relation to 
LCMV-GP118 are indicated. Great structural similarity is observed between these 
two complexes, both in terms of topography and electrostatic potential over the 
TCR-interacting surface. Note that other subtle structural differences might exist 
but are not well captured by this representation of the complexes.
FigUre s4 | Specific interaction with a prominent peptide amino acid.  
(a) Surface of the IAV-PA224:H-2Db complex (spicy peptide) according to a crystal 
structure obtained in the absence of the TCR (PDB code 1WBY). (B) Surface  
of the same complex according to a crystal structure obtained in the presence  
of the TCR (PDB code 3PQY). (C) Cartoon depiction of the 3PQY structure 
highlighting TCR amino acid residues that interact directly with a prominent 
arginine at the peptide (R7), forming a negatively charged cavity. Side chain  
of amino acid R7 is depicted in ball and stick. TCR and MHC domains are 
indicated, and green arrows highlight the location of amino acid residue R7. 
Electrostatic potentials were computed with Grasp2 (64).
FigUre s5 | Crystal-based H-2Db-restricted clustering. Structure-based 
hierarchical clustering performed with pvclust. Each putative cluster is 
represented by a specific edge (gray numbers), in order of increasing heights  
(y axis). Cluster confidence is measured with two p-values, approximately 
unbiased (AU) and bootstrap probabilities (BP). Peptide abbreviation and the 
respective PDB code for each crystal structure (in blue) are provided. Lines 
highlighted in purple indicate structures with greater structural similarity  
(as represented in Figure 1).
FigUre s6 | Extended HLA-A*02:01-restricted clustering. Structure-based 
hierarchical clustering performed with pvclust. Each putative cluster is 
represented by a specific edge (gray numbers), in order of increasing heights  
(y axis). Cluster confidence is measured with two p-values, approximately 
unbiased (AU) and bootstrap probabilities (BP). Abbreviation of crystal structures 
includes their PDB code (in blue), while “Mod” indicates modeled structures. 
Lines highlighted in purple indicate structures with greater structural similarity  
(as represented in Figure 1).
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